Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors

Authors

Rachel Sanborn, ProvidenceFollow
See full list of authors in comments

Document Type

Abstract

Publication Date

11-1-2023

Keywords

oregon; chiles

Clinical Institute

Cancer

Department

Oncology

Comments

Sanborn RE, Furqan M, Laux D, Sharma M, Olson D, Berz D, Hauke RJ, Massarelli E, Steuer C, Davis E, Iams WT, Thompson J, Hamm J, Andrianov V, O’Neill B, Durana YDD, Tolcher AW. SITC Annual Meeting; November 1-5; San Diego, CA. 2023;11(Suppl 1): 748.

Recommended Citation

Sanborn, Rachel and See full list of authors in comments, "Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors" (2023). Articles, Abstracts, and Reports. 8365.
https://digitalcommons.providence.org/publications/8365